Antibody Approach To CGRP Offers Safer Mode For Migraine Prevention, Labrys Says
This article was originally published in The Pink Sheet Daily
Labrys is ready to advance a monoclonal antibody to Phase II for prevention of chronic migraine, after releasing pooled safety from five Phase I trials conducted by Pfizer.
You may also be interested in...
New venture firm venBio, which closed its inaugural $200 million fund in 2010, has begun the new year by unveiling two start ups with very different business propositions.
Meanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.
Sandoz has heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” after completing its long journey towards independence by separating from former parent company Novartis.